Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc. (Nasdaq: NBIX)
Filing Type: Form 8-K (Current Report)
Date of Report: April 5, 2026
Event: Entry into a Material Definitive Agreement to acquire Soleno Therapeutics, Inc.
Key Financial Metrics and Transaction Terms
This filing details a proposed acquisition rather than periodic financial results. Key transaction metrics include:
- Offer Price: $53.00 per share in cash for all outstanding shares of Soleno Therapeutics, Inc.
- Transaction Structure: Cash tender offer followed by a merger under Section 251(h) of the Delaware General Corporation Law.
- Financing: The offer is not subject to any financing condition.
- Termination Fee (Soleno to Neurocrine): $95,250,000 payable if Soleno terminates to accept a superior proposal.
- Reverse Termination Fee (Neurocrine to Soleno): $141,500,000 payable if Neurocrine terminates due to failure to satisfy antitrust waiting periods or governmental restraints.
- Supporting Stockholders: Soleno CEO Anish Bhatnagar and former CFO James Mackaness hold approximately 1.01% of outstanding shares and have agreed to tender and support the transaction.
Note: The filing text does not provide Neurocrine's current revenue, profit, cash flow, or debt levels.
Material Changes and Conditions
The primary material change is the execution of the Merger Agreement. The transaction is subject to several material conditions, including:
- Receipt of valid tenders representing more than 50% of Soleno's outstanding shares.
- Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act).
- Absence of any governmental order restraining the transaction.
- No material adverse effect on Soleno.
- Accuracy of representations and warranties.
Soleno has agreed to "no-shop" restrictions, prohibiting the solicitation of alternative acquisition proposals, subject to fiduciary out provisions for superior proposals.
Guidance, Outlook, and Risks
Management Commentary: The Soleno Board of Directors recommends that stockholders accept the offer. Neurocrine intends to commence the tender offer within ten business days of the agreement date and keep it open for twenty business days.
Risks and Contingencies:
- Regulatory Approval: Uncertainty regarding the timing and outcome of antitrust reviews.
- Transaction Completion: Risk that the tender offer fails to meet the 50% threshold or that closing conditions are not satisfied.
- Integration: Potential difficulties in integrating Soleno's operations and realizing anticipated benefits.
- Market Reaction: Potential negative impact on Neurocrine's stock price if benefits are not realized as expected.
- Product Development: Risks related to the commercial uptake of Soleno's product, VYKAT XR (diazoxide choline), and future clinical trial outcomes.
Investor Verification Checklist
- Verify the final tender offer materials (Schedule TO) and Soleno's Solicitation/Recommendation Statement (Schedule 14D-9) once filed with the SEC.
- Confirm the percentage of Soleno shares tendered to ensure the >50% closing condition is met.
- Monitor regulatory filings for updates on HSR Act waiting periods and antitrust clearance.
- Review Neurocrine's most recent 10-K and 10-Q filings to assess liquidity and ability to fund the cash transaction.
- Check for any competing acquisition proposals that might trigger Soleno's fiduciary out provisions.